Results 151 to 160 of about 8,158 (292)

Dysfunctional Lipid-Induced Secretion of Glucagon-Like Peptide-2(GLP-2), but Not of Incretins Glucagon-Like Peptide-1(GLP-1)/Glucose-Dependent Insulinotropic Polypeptide(GIP), Promotes Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) Onset and Progression Through Gut Barrier Disruption and Endotoxemia. [PDF]

MedComm (2020)
Musso G, Pinach S, Mella A, De Michieli F, Calabrese A, Trifiro D, Petrangolini G, Cassader M, Mariano F, Gambino R.   +9 more
europepmc   +1 more source

A Systematic Review and Meta‐Analysis of Semaglutide Effects on Adipose Tissue and Emerging Effects on Brain and Cognition

Obesity Reviews, EarlyView.
ABSTRACT Background In 2023 and 2024, research into semaglutide (SEMA), an antiobesity and antidiabetic medication, indicated potential benefits beyond its approved uses, particularly in preventing Alzheimer's disease (AD). This highlights the link between obesity and AD development.
Amene Saghazadeh, Mahsa Dolatshahi, Soheil Mohammadi, Sara Hosseinzadeh Kassani, Mahshid Naghashzadeh, Joseph E. Ippolito, Claude B. Sirlin, Bettina Mittendorfer, Matthew R. Brier, Suzanne E. Schindler, John C. Morris, Danny Mou, Hani Charles Soudah, Tammie L. S. Benzinger, Cyrus A. Raji   +14 more
wiley   +1 more source

A DYRK inhibitor ameliorates glucose homeostasis and increases incretin-producing cells in diabetic mice. [PDF]

J Mol Endocrinol
Terasaki M, Zhou Q, Andersson O, Yamagishi SI.   +3 more
europepmc   +1 more source

Effects of Glucagon‐Like Peptide‐1 Receptor Agonists (Mono and Combination Therapy) on Energy Expenditure: A Scoping Review

Obesity Reviews, EarlyView.
ABSTRACT Introduction Weight loss results in reduced energy expenditure (EE) due to body composition alterations (e.g., fat‐free mass and fat mass losses) and mass‐independent adaptations in EE (e.g., hormones). Glucagon‐like peptide‐1 receptor agonists (GLP‐1RA) are indicated for obesity management; however, their effects on EE remain unclear ...
Flavio T. Vieira, ZhiDi Deng, Manfred J. Muller, Giovanna G. L. Bergamasco, Sarah Cawsey, Melania Manco, Steven B. Heymsfield, Carla M. Prado, Andrea M. Haqq   +8 more
wiley   +1 more source

Incretin Mimetics as Potential Therapeutics for Concussion and Traumatic Brain Injury: A Narrative Review. [PDF]

Int J Mol Sci
Sipos S, Jerkic M, Rotstein OD, Schweizer TA.   +3 more
europepmc   +1 more source

Association of Glucagon‐Like Peptide‐1 Receptor Agonists and Suicidality: A Systematic Review

Obesity Reviews, EarlyView.
ABSTRACT Introduction Increased risk of suicidality has been reported in association with glucagon‐like peptide receptor agonist (GLP‐1 RA) prescription. Herein, we conducted a comprehensive review evaluating reports of GLP‐1 RA prescription and suicidality.
Hezekiah C. T. Au, Yang Jing Zheng, Gia Han Le, Sabrina Wong, Kayla M. Teopiz, Angela T. H. Kwan, Joshua D. Rosenblat, Rodrigo B. Mansur, Hayun Choi, Roger S. McIntyre   +9 more
wiley   +1 more source

Advantages of Skeletal Muscle Preservation in Settings of Weight Loss. [PDF]

Aging Cell
Glass DJ.
europepmc   +1 more source

The incretin revolution

The Journal of AMD
Negli ultimi anni, l’obesità è stata ridefinita come una malattia cronica, recidivante e multifattoriale, superando il modello obsoleto del semplice squilibrio energetico. Questa nuova visione ha coinciso con una rivoluzione terapeutica guidata dalla farmacoterapia su base incretinica.
openaire   +1 more source

EffectS of Lifestyle Interventions in Older PEople With Obesity (Effective SLOPE): a Systematic Review With Network Meta‐Analyses

Obesity Reviews, EarlyView.
ABSTRACT Background/Aim We conducted a systematic review with network meta‐analyses (NMA) summarizing the effects and safety of lifestyle interventions containing nutrition (NUT; e.g., calorie restriction), exercise (EX; e.g., aerobic/resistance exercise) and behavior change interventions (BCI; e.g., behavioral therapy) on physical function, body ...
Gabriel Torbahn, Daniel Schoene, Isabel Galicia Ernst, Lukas Schwingshackl, Gerta Rücker, Helge Knüttel, Wolfgang Kemmler, Cornel C. Sieber, John A. Batsis, Dennis T. Villareal, Nanette Stroebele‐Benschop, Dorothee Volkert, Eva Kiesswetter   +12 more
wiley   +1 more source

Low Weight Loss Response to Incretin Analogs: A Systematic Review

Obesity Reviews, EarlyView.
ABSTRACT The development of GLP‐1 and GIP analogs has been a significant breakthrough in type 2 diabetes and obesity pharmacotherapy. However, individual responses to these medications can vary widely. This systematic review examines factors associated with low or no weight loss response to GLP‐1 and GIP analogs. Key predictors of poor response include
Pamela S. Gaskin, Peter S. Chami
wiley   +1 more source